Manufacturing and device options for the delivery of biotherapeutics

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 27, Issue 5, 2014, Pages 315-328

  Hoe, Susan ^a   Boraey, Mohammed A ^a   Ivey, James W ^a   Finlay, Warren H ^a   Vehring, Reinhard ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

bacteriophages; biotherapeutics; droplet drying kinetics; dry powder inhaler; metered dose inhaler; predictive approach; process modeling; spray drying

Indexed keywords

AEROSOL; BACTERIOPHAGE; BIOLOGICAL ACTIVITY; CHEMICAL REACTION; CLINICAL TRIAL (TOPIC); COLD; DEGRADATION KINETICS; DESICCATION; DRUG DELIVERY DEVICE; DRUG DESIGN; DRUG FORMULATION; DRUG STABILITY; DRY POWDER; DRY POWDER INHALER; ENERGY BALANCE; EQUIPMENT DESIGN; FREEZE DRYING; HEAT STRESS; HUMAN; LUNG; MECHANICAL STRESS; METERED DOSE INHALER; NEBULIZATION; NEBULIZER; PATIENT SATISFACTION; PRESERVATION; PROCESS DESIGN; PROTEIN DENATURATION; RESPIRATORY DRUG ADMINISTRATION; REVIEW; SPRAY DRYING; SUPERCRITICAL FLUID; TEMPERATURE STRESS; BIOLOGICAL THERAPY; DEVICES; DRUG DELIVERY SYSTEM; INHALATIONAL DRUG ADMINISTRATION; LUNG DISEASES; MATERIALS; PROCEDURES;

ADMINISTRATION, INHALATION; BIOLOGICAL THERAPY; DRUG DELIVERY SYSTEMS; EQUIPMENT DESIGN; HUMANS; LUNG DISEASES; MANUFACTURED MATERIALS; NEBULIZERS AND VAPORIZERS; STRESS, MECHANICAL;

EID: 84907450085     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2013.1090     Document Type: Review

References (118)

1. McElroy MC, Kirton C, Gliddon D, and Wolff RK: Inhaled biopharmaceutical drug development: nonclinical considerations and case studies. Inhal Toxicol. 2013;25:219-232.
2. Aggarwal SR: What's fueling the biotech engine-2011 to 2012. Nat Biotechnol. 2012;30:1191-1197.
3. Depreter F, Pilcer G, and Amighi K: Inhaled proteins: challenges and perspectives. Int J Pharm. 2013;447:251-280.
4. Máiz L, Girón RM, Olveira C, Quintana E, Lamas A, Pastor D, Cantón R, and Mensa J: Inhaled antibiotics for the treatment of chronic bronchopulmonary Pseudomonas aeruginosa infection in cystic fibrosis: systematic review of randomised controlled trials. Expert Opin Pharmacother. 2013;14:1135-1149.
5. Sabin AB, Arechiga AF, Decastro JF, Sever JL, Madden DL, Shekarchi I, and Albrecht P: Successful immunization of children with and without maternal antibody by aerosolized measles-vaccine. 1. Different results with undiluted human-diploid cell and chick-embryo fibroblast vaccines. JAMA. 1983;249:2651-2662.
6. Lin WH, Griffin DE, Rota PA, Papania M, Cape SP, Bennett D, Quinn B, Sievers RE, Shermer C, Powell K, Adams RJ, Godin S, and Winston S: Successful respiratory immunization with dry powder live-attenuated measles virus vaccine in rhesus macaques. Proc Natl Acad Sci USA. 2011;108:2987-2992.
7. Hickey AJ: Back to the future: inhaled drug products. J Pharm Sci. 2013;102:1165-1172.
8. Soares S, Costa A, and Sarmento B: Novel non-invasive methods of insulin delivery. Expert Opin Drug Deliv. 2012;9:1539-1558.
9. Hawe A, Wiggenhorn M, van de Weert M, Garbe JHO, Mahler HC, and Jiskoot W: Forced degradation of therapeutic proteins. J Pharm Sci. 2012;101:895-913.
10. Manning MC, Chou DK, Murphy BM, Payne RW, and Katayama DS: Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27:544-575.
11. Abbas SA, Sharma VK, Patapoff TW, and Kalonia DS: Opposite effects of polyols on antibody aggregation: thermal versus mechanical stresses. Pharm Res. 2012;29: 683-694.
12. Arakawa T, Prestrelski SJ, Kenney WC, and Carpenter JF: Factors affecting short-term and long-term stabilities of proteins. Adv Drug Deliv Rev. 2001;46:307-326.
13. Wang W: Lyophilization and development of solid protein pharmaceuticals. Int J Pharm. 2000;203:1-60.
14. Bhatnagar BS, Bogner RH, and Pikal MJ: Protein stability during freezing: separation of stresses and mechanisms of protein stabilization. Pharm Dev Technol. 2007;12:505-523.
15. Hoe S, Semler DD, Goudie AD, Lynch KH, Matinkhoo S, Finlay WH, Dennis JJ, and Vehring R: Respirable bacte-riophages for the treatment of bacterial lung infections. J Aerosol Med Pulm Drug Deliv. 2013 [Epub ahead of print].
16. Abdul-Fattah AM, Kalcinia DS, and Pikal MI: The challenge of drying method selection for protein pharmaceuticals: product quality implications. J Pharm Sci. 2007; 96:1886-1916.
17. Tawfeek HM, Evans AR, Iftikhar A, Mohammed AR, Shabir A, Somavarapu S, Hutcheon GA, and Saleem IY: Dry powder inhalation of macromolecules using novel PEG-co-polyester microparticle carriers. Int J Pharm. 2013;441:611-619.
18. Amorij JP, Huckriede A, Wischut J, Frijlink HW, and Hinrichs WLJ: Development of stable influenza vaccine powder formulations: challenges and possibilities. Pharm Res. 2008;25:1256-1273.
19. Grasmeijer N, Stankovic M, de Waard H, Frijlink HW, and Hinrichs WLJ: Unraveling protein stabilization mechanisms: vitrification and water replacement in a glass transition temperature controlled system. Biochim Biophys Acta. 2013;1834:763-769.
20. Bekard IB, Asimakis P, Bertolini J, and Dunstan DE: The effects of shear flow on protein structure and function. Biopolymers. 2011;95:733-745.
21. Bekard IB, and Dunstan DE: Shear-induced deformation of bovine insulin in Couette flow. J Phys Chem B. 2009; 113:8453-8457.
22. Chung SW, Hil-lal TA, and Byun Y: Strategies for non-invasive delivery of biologics. J Drug Target. 2012;20:481-501.
23. Ogáin ON, Li JH, Tajber L, Corrigan OI, and Healy AM: Particle engineering of materials for oral inhalation by dry powder inhalers. I-Particles of sugar excipients (trehalose and raffinose) for protein delivery. Int J Pharm. 2011;405: 23-35.
24. Shoyele SA, and Cawthome S: Particle engineering techniques for inhaled biopharmaceuticals. Adv Drug Deliv Rev. 2006;58:1009-1029.
25. D'Souza DH, Su XW, Roach A, and Harte F: High-pressure homogenization for the inactivation of human enteric virus surrogates. J Food Prot. 2009;72:2418-2422.
26. Tarara TE, Hartman MS, Gill H, Kennedy AA, and Weers JG: Characterization of suspension-based metered dose inhaler formulations composed of spray-dried budesonide microcrystals dispersed in HFA-134a. Pharm Res. 2004;21: 1607-1614.
27. Avestin Inc. High Pressure Homogenizers up to 2000bar/30000psi. Available at www.avestin.com/English/products.html. Accessed July 23, 2013.
28. Ashton L, Dusting J, Imomoh E, Balabani S, and Blanch EW: Shear-induced unfolding of lysozyme monitored in situ. Biophys J. 2009;96:4231-4236.
29. Brown LR: Commercial challenges of protein drug delivery. Expert Opin Drug Deliv. 2005;2:29-42.
30. Calo-Fernández B, and Martínez-Hurtado JL: Biosimilars: company strategies to capture value from the biologics market. Pharmaceuticals. 2012;5:1393-1408.
31. Garcia-Contreras L, and Smyth HDC: Liquid-spray or dry-powder systems for inhaled delivery of peptide and proteins? Am J Drug Deliv. 2005;3:29-45.
32. Jezek J, Darton NJ, Derham BK, Royle N, and Simpson I: Biopharmaceutical formulations for pre-filled delivery devices. Expert Opin Drug Deliv. 2013;10:811-828.
33. Desai TR, Hancock REW, and Finlay WH: A facile method of delivery of liposomes by nebulization. J Control Release. 2002;84:69-78.
34. Niven RW: Delivery of biotherapeutics by inhalation aerosol. Crit Rev Ther Drug Carrier Syst. 1995;12:151-231.
35. Wang ZL, Finlay WH, Peppler MS, and Sweeney LG: Powder formation by atmospheric spray-freeze-drying. Powder Technol. 2006;170:45-52.
36. Taylor G, and Gumbleton M: Aerosols for macromolecule delivery: design challenges and solutions. Am J Drug Deliv. 2004;2:143-155.
37. Girotra P, Singh SK, and Nagpal K: Supercritical fluid technology: a promising approach in pharmaceutical research. Pharm Dev Technol. 2013;18:22-38.
38. Ameri M, and Maa YF: Spray drying of biopharmaceu-ticals: stability and process considerations. Dry Technol. 2006;24:763-768.
39. Sou T, Meeusen EN, de Veer M, Morton DAV, Kaminskas LM, and McIntosh MP: New developments in dry powder pulmonary vaccine delivery. Trends Biotechnol. 2011; 29:191-198.
40. Sadrzadeh N, Miller DP, Lechuga-Ballesteros D, Harper NJ, Stevenson CL, and Bennett DB: Solid-state stability of spray-dried insulin powder for inhalation: chemical kinetics and structural relaxation modeling of Exubera above and below the glass transition temperature. J Pharm Sci. 2010;99:3698-3710.
41. Learoyd TP, Burrows JL, French E, and Seville PC: Chit-osan-based spray-dried respirable powders for sustained delivery of terbutaline sulfate. Eur J Pharm Biopharm. 2008;68:224-234.
42. Mohajel N, Najafabadi AR, Azadmanesh K, Vatanara A, Moazeni E, Rahimi A, and Gilani K: Optimization of a spray drying process to prepare dry powder microparticles containing plasmid nanocomplex. Int J Pharm. 2012; 423:577-585.
43. Muttil P, Prego C, Garcia-Contreras L, Pulliam B, Fallon JK, Wang CC, Hickey AJ, and Edwards D: Immunization of guinea pigs with novel hepatitis B antigen as nanoparticle aggregate powders administered by the pulmonary route. AAPS J. 2010;12:330-337.
44. Muttil P, Pulliam B, Garcia-Contreras L, Fallon JK, Wang CC, Hickey AJ, and Edwards DA: Pulmonary immunization of guinea pigs with diphtheria CRM-197 antigen as nanoparticle aggregate dry powders enhance local and systemic immune responses. AAPS J. 2010;12:699-707.
45. Hamishehkar H, Emami J, Najafabadi AR, Gilani K, Minaiyan M, Mandavi H, and Nokhodchi A: Influence of carrier particle size, carrier ratio and addition of fine ternary particles on the dry powder inhalation performance of insulin-loaded PLGA microcapsules. Powder Technol. 2010;201:289-295.
46. Paudel A, Worku ZA, Meeus J, Guns S, and Van den Mooter G: Manufacturing of solid dispersions of poorly water soluble drugs by spray drying: formulation and process considerations. Int J Pharm. 2013;453:253-284.
47. Chew NY, Shekunov BY, Tong HH, Chow AH, Savage C, Wu J, and Chan HK: Effect of amino acids on the dispersion of disodium cromoglycate powders. J Pharm Sci. 2005; 94:2289-2300.
48. Seville PC, Learoyd TP, Li HY, Williamson IJ, and Birchall JC: Amino acid-modified spray-dried powders with enhanced aerosolisation properties for pulmonary drug delivery. Powder Technol. 2007;178:40-50.
49. Boraey MA, Hoe S, Sharif H, Miller DP, Lechuga-Balles-teros D, and Vehring R: Improvement of the dispersibility of spray-dried budesonide powders using leucine in an ethanol-water cosolvent system. Powder Technol. 2013; 236:171-178.
50. Feng AL, Boraey MA, Gwin MA, Finlay PR, Kuehl PJ, and Vehring R: Mechanistic models facilitate efficient development of leucine containing microparticles for pulmonary drug delivery. Int J Pharm. 2011;409:156-163.
51. You Y, Zhao M, Liu G, and Tang X: Physical characteristics and aerosolization performance of insulin dry powders for inhalation prepared by a spray drying method. J Pharm Pharmacol. 2007;59:927-934.
52. Minne A, Boireau H, Horta MJ, and Vanbever R: Optimization of the aerosolization properties of an inhalation dry powder based on selection of excipients. Eur J Pharm Bio-pharm. 2008;70:839-844.
53. Sou T, Orlando L, McIntosh MP, Kaminskas LM, and Morton DA: Investigating the interactions of amino acid components on a mannitol-based spray-dried powder formulation for pulmonary delivery: a design of experiment approach. Int J Pharm. 2011;421:220-229.
54. Lechuga-Ballesteros D, Charan C, Stults CLM, Stevenson CL, Miller DP, Vehring R, Tep V, and Kuo MC: Trileucine improves aerosol performance and stability of spray-dried powders for inhalation. J Pharm Sci. 2008;97:287-302.
55. Li HY, Neill H, Innocent R, Seville P, Williamson I, and Birchall JC: Enhanced dispersibility and deposition of spray-dried powders for pulmonary gene therapy. J Drug Target. 2003;11:425-432.
56. Rabbani NR, and Seville PC: The influence of formulation components on the aerosolisation properties of spray-dried powders. J Control Release. 2005;110:130-140.
57. Jin TH, Tsao E, Goudsmit J, Dheenadhayalan V, and Sadoff J: Stabilizing formulations for inhalable powders of an adenovirus 35-vectored tuberculosis (TB) vaccine (AERAS-402). Vaccine. 2010;28:4369-4375.
58. Wong YL, Sampson S, Germishuizen WA, Goonesekera S, Caponetti G, Sadoff J, Bloom BR, and Edwards D: Drying a tuberculosis vaccine without freezing. Proc Natl Acad Sci USA. 2007;104:2591-2595.
59. Shur J, Nevell TG, Ewen RJ, Price R, Smith A, Barbu E, Conway JH, Carroll MP, Shute JK, and Smith JR Cospray-dried unfractionated heparin with L-leucine as a dry powder inhaler mucolytic for cystic fibrosis therapy. J Pharm Sci. 2008;97:4857-4868.
60. Thai A, Xiao J, Ammit AJ, and Rohanizadeh R Development of inhalable formulations of anti-inflammatory drugs to potentially treat smoke inhalation injury in burn victims. Int J Pharm. 2010;389:41-52.
61. Grenha A, Remunan-Lopez C, Carvalho ELS, and Seijo B: Microspheres containing lipid/chitosan nanoparticles complexes for pulmonary delivery of therapeutic proteins. Eur J Pharm Biopharm. 2008;69:83-93.
62. Geller DE, Weers J, and Heuerding S: Development of an inhaled dry-powder formulation of tobramycin using Pul-moSphere™ technology. J Aerosol Med Pulm Drug Deliv. 2011;24:175-182.
63. Smith DJ, Bot S, Dellamary L, and Bot A: Evaluation of novel aerosol formulations designed for mucosal vaccination against influenza virus. Vaccine. 2003;21:2805-2812.
64. Maa YF, Nguyen PAT, and Hsu SW: Spray-drying of air-liquid interface sensitive recombinant human growth hormone. J Pharm Sci. 1998;87:152-159.
65. Maa YF, and Hsu CC: Effect of high shear on proteins. Biotechnol Bioeng. 1996;51:458-465.
66. Ghandi A, Powell IB, Howes T, Chen XD, and Adhikari B: Effect of shear rate and oxygen stresses on the survival of Lactococcus lactis during the atomization and drying stages of spray drying: a laboratory and pilot scale study. J Food Eng. 2012;113:194-200.
67. Vandenheuvel D, Singh A, Vandersteegen K, Klumpp J, Lavigne R, and Van den Mooter G: Feasibility of spray drying bacteriophages into respirable powders to combat pulmonary bacterial infections. Eur J Pharm Biopharm. 2013;84:578-582.
68. Seed KD, and Dennis JJ: Experimental bacteriophage therapy increases survival of Galleria mellonella larvae infected with clinically relevant strains of the Burkholderia cepacia complex. Antimicrob Agents Chemother. 2009;53:2205-2208.
69. Dellamary LA, Tarara TE, Smith DJ, Woelk CH, Adractas A, Costello ML, Gill H, and Weers JG: Hollow porous particles in metered dose inhalers. Pharm Res. 2000;17:168-174.
70. Weers JG, Tarara TE, and Clark AR: Design of fine particles for pulmonary drug delivery. Expert Opin Drug Deliv. 2007;4:297-313.
71. Matinkhoo S, Lynch KH, Dennis JJ, Finlay WH, and Vehring R: Spray-dried respirable powders containing bacteriophages for the treatment of pulmonary infections. J Pharm Sci. 2011;100:5197-5205.
72. Golshahi L, Lynch KH, Dennis JJ, and Finlay WH: In vitro lung delivery of bacteriophages KS4-M and FKZ using dry powder inhalers for treatment of Burkholderia cepacia complex and Pseudomonas aeruginosa infections in cystic fibrosis. J Appl Microbiol. 2011;110:106-117.
73. Ivey JW, and Vehring R: The use of modeling in spray drying of emulsions and suspensions accelerates formulation and process development. Comput Chem Eng. 2010;34:1036-1040.
74. Seaver AE: Closed form equations for the evaporation rate and droplet size of Knudsen droplets. Aerosol Sci Technol. 1984:177-185.
75. Vehring R, Foss WR, and Lechuga-Ballesteros D: Particle formation in spray drying. J Aerosol Sci. 2007:728-746.
76. Dobry DE, Settell DM, Baumann JM, Ray RJ, Graham LJ, and Beyerinck RA: A model-based methodology for spray-drying process development. J Pharm Innov. 2009;4:133-142.
77. Miller DP, de Pablo JJ, and Corti H: Thermophysical properties of trehalose and its concentrated aqueous solutions. Pharm Res. 1997;14:578-590.
78. Hancock BC, Shamblin SL, and Zografi G: Molecular mobility of amorphous pharmaceutical solids below their glass transition temperatures. Pharm Res. 1995;12:799-806.
79. Yoshioka S, and Aso Y: A quantitative assessment of the significance of molecular mobility as a determinant for the stability of lyophilized insulin formulations. Pharm Res. 2005;22:1358-1364.
80. Yoshioka S, Miyazaki T, and Aso Y: b-Relaxation of insulin molecule in lyophilized formulations containing trehalose or dextran as a determinant of chemical reactivity. Pharm Res. 2006;23:961-966.
81. Yoshioka S, Aso Y, and Miyazaki T: Negligible contribution of molecular mobility to the degradation rate of insulin lyophilized with poly(vinylpyrrolidone). J Pharm Sci. 2006;95:939-943.
82. Simperler A, Kornherr A, Chopra R, Jones W, Motherwell WD, and Zifferer G: The glass transition temperatures of amorphous trehalose-water mixtures and the mobility of water: an experimental and in silico study. Carbohydr Res. 2007;342:1470-1479.
83. Vehring R: Pharmaceutical particle engineering via spray drying. Pharm Res. 2008;25:999-1022.
84. Kolodkin-Gal I, Romero D, Cao S, Clardy J, Kolter R, and Losick R: D-Amino acids trigger biofilm disassembly. Science. 2010;328:627-629.
85. Sanchez Z, Tani A, and Kimbara K: Extensive reduction of cell viability and enhanced matrix production in Pseudo-monas aeruginosa PAO1 flow biofilms treated with a D-amino acid mixture. Appl Environ Microbiol. 2013; 79:1396-1399.
86. Carvalho TC, Peters JI, and Williams RO 3rd: Influence of particle size on regional lung deposition-what evidence is there? Int J Pharm. 2011;406:1-10.
87. Chow AH, Tong HH, Chattopadhyay P, and Shekunov BY: Particle engineering for pulmonary drug delivery. Pharm Res. 2007;24:411-437.
88. Friebel C, and Steckel H: Single-use disposable dry powder inhalers for pulmonary drug delivery. Expert Opin Drug Deliv. 2010;7:1359-1372.
89. thInternational Congress, Chapel Hill, NC, April 6-10, 2013; J Aerosol Med Pulm Drug Deliv. 2013;26:A30.
90. Matinkhoo S, Hoe S, Boraey MA, Shamsaddini-Shahrbabak A, Finlay WH, and Vehring R: Spray drying D-amino acids to develop respirable dry powder for the treatment of Pseudomonas aeruginosa biofilms. Presented at American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition, Chicago, IL, October 15, 2012.
91. Adi S, Adi H, Tang P, Traini D, Chan HK, and Young PM: Micro-particle corrugation, adhesion and inhalation aerosol efficiency. Eur J Pharm Sci. 2008;35:12-18.
92. Weiler C, Egen M, Trunk M, and Langguth P: Force control and powder dispersibility of spray dried particles for inhalation. J Pharm Sci. 2010;99:303-316.
93. Hasan MA, and Lange CF: Estimating in vivo airway surface liquid concentration in trials of inhaled antibiotics. J Aerosol Med. 2007;20:282-293.
94. Hoe S, Ivey JW, Boraey MA, Shamsaddini-Shahrbabak A, Javaheri E, Matinkhoo S, Finlay WH, and Vehring R: Use of a fundamental approach to spray-drying formulation design to facilitate the development of multi-component dry powder aerosols for respiratory drug delivery. Pharm Res. 2013 [Epub ahead of print].
95. Finlay WH, Lange CF, King M, and Speert DP: Lung delivery of aerosolized dextran. Am J Respir Crit Care Med. 2000;161:91-97.
96. Hoe S, Ivey JW, Boraey MA, Shamsaddini-Shahrbabak A, Matinkhoo S, Finlay WH, and Vehring R: A rational approach to spray drying multi-component formulations containing low solubility actives. Respiratory Drug Delivery Europe 2013, Vol. 2, pp. 393-396; Berlin, Germany.
97. Chan JGY, Traini D, Chan HK, Young PM, and Kwok PCL: Delivery of high solubility polyols by vibrating mesh nebulizer to enhance mucociliary clearance. J Aerosol Med Pulm Drug Deliv. 2012;25:297-305.
98. Perera AD, Kapitza C, Nosek L, Fishman RS, Shapiro DA, Heise T, and Heinemann L: Absorption and metabolic effect of inhaled insulin: intrapatient variability after inhalation via the Aerodose Insulin Inhaler in patients with type 2 diabetes. Diabetes Care. 2002;25:2276-2281.
99. Golshahi L, Seed KD, Dennis JJ, and Finlay WH: Toward modern inhalational bacteriophage therapy: nebulization of bacteriophages of Burkholderia cepacia complex. J Aerosol Med Pulm Drug Deliv. 2008;21:351-360.
100. Watts AB, McConville JT, and Williams RO: Current therapies and technological advances in aqueous aerosol drug delivery. Drug Dev Ind Pharm. 2008;34:913-922.
101. Alhanout K, Brunel JM, Dubus JC, Rolain JM, and Andrieu V: Suitability of a new antimicrobial aminosterol formulation for aerosol delivery in cystic fibrosis. J Antimicrob Chemother. 2011;66:2797-2800.
102. Kim D, Mudaliar S, Chinnapongse S, Chu N, Boies SM, Davis T, Perera AD, Fishman RS, Shapiro DA, and Henry R: Dose-response relationships of inhaled insulin delivered via the Aerodose insulin inhaler and subcutaneously injected insulin in patients with type 2 diabetes. Diabetes Care. 2003;26:2842-2847.
103. Khafagy E-S, Morishita M, Onuki Y, and Takayama K: Current challenges in non-invasive insulin delivery systems: a comparative review. Adv Drug Deliv Rev. 2007; 59:1521-1546.
104. Amorij JP, Hinrichs W, Frijlink HW, Wilschut JC, and Huckriede A: Needle-free influenza vaccination. Lancet Infect Dis. 2010;10:699-711.
105. Atkins PJ: Dry powder inhalers: an overview. Respir Care. 2005;50:1304-1312.
106. de Boer AH, Hagedoorn P, Westerman EM, Le Brun PPH, Heijerman HGM, and Frijlink HW: Design and in vitro performance testing of multiple air classifier technology in a new disposable inhaler concept (Twincer®) for high powder doses. Eur J Pharm Sci. 2006;28:171-178.
107. Saluja V, Amorij JP, Kapteyn JC, de Boer AH, Frijlink HW, and Hinrichs WLJ: A comparison between spray drying and spray freeze drying to produce an influenza subunit vaccine powder for inhalation. J Control Release. 2010;144:127-133.
108. de Boer AH, Hagedoorn P, Gjaltema D, Goede J, and Frijlink HW: Air classifier technology (ACT) in dry powder inhalation: Part 1. Introduction of a novel force distribution concept (FDC) explaining the performance of a basic air classifier on adhesive mixtures. Int J Pharm. 2003;260: 187-200.
109. Westerman EM, de Boer AH, Le Brun PPH, Touw DJ, Frijlink HW, and Heijerman HGM: Dry powder inhalation of colistin sulphomethate in healthy volunteers: a pilot study. Int J Pharm. 2007;335:41-45.
110. Westerman EM, De Boer AH, Le Brun PPH, Touw DJ, Roldaan AC, Frijlink HW, and Heijerman HGM: Dry powder inhalation of colistin in cystic fibrosis patients: a single dose pilot study. J Cyst Fibros. 2007; 6:284-292.
111. Bains BK, Birchall JC, Toon R, and Taylor G: In vitro reporter gene transfection via plasm in DNA delivered by metered dose inhaler. J Pharm Sci. 2010;99:3089-3099.
112. Nyambura BK, Kellaway IW, and Taylor KMG: Insulin nanoparticles: stability and aerosolization from pressurized metered dose inhalers. Int J Pharm. 2009;375:114-122.
113. Myrdal PB, Karlage KL, Stein SW, Brown BA, and Haynes A: Optimized dose delivery of the peptide cyclosporine using hydrofluoroalkane-based metered dose inhalers. J Pharm Sci. 2004;93:1054-1061.
114. Zheng JY, Fulu MY, Lee DY, Barber TE, and Adjei AL: Pulmonary peptide delivery: effect of taste-masking ex-cipients on leuprolide suspension metered-dose inhalers. Pharm Dev Technol. 2001;6:521-530.
115. Shoyele SA, and Slowey A: Prospects of formulating pro-teins/peptides as aerosols for pulmonary drug delivery. Int J Pharm. 2006;314:1-8.
116. Tan YH, Yang ZW, Peng XS, Xin F, Xu YH, Feng M, Zhao CS, Hu HY, and Wu CB: A novel bottom-up process to produce nanoparticles containing protein and peptide for suspension in hydrofluoroalkane propellants. Int J Pharm. 2011;413:167-173.
117. O'Donnell KP, and Williams RO: Pulmonary dispersion formulations: the impact of dispersed powder properties on pressurized metered dose inhaler stability. Drug Dev Ind Pharm. 2013;39:413-424.
118. MedicinesComplete. London: Pharmaceutical Press. Available at www.medicinescomplete.com. Accessed July 30, 2013.